Supriya Lifescience Ltd
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Figures in Rs. Crores
(S): Standalone figures, shown where consolidated figures are not available.
Profit & Loss
Figures in Rs. Crores
| Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | 828 | |
| Sales growth | +16% | +30% | +12% | +26% | +35% | -13% | +24% | +22% | +19% | |
| 166 | 191 | 213 | 213 | 218 | 316 | 332 | 394 | 436 | 533 | |
| Operating Profit | 17 | 22 | 65 | 98 | 173 | 214 | 129 | 176 | 261 | 295 |
| OPM % | 9% | 10% | 23% | 32% | 44% | 40% | 28% | 31% | 37% | 36% |
| 7 | 9 | 8 | 11 | 5 | 8 | 9 | 11 | 10 | 11 | |
| Interest | 12 | 11 | 10 | 7 | 4 | 4 | 3 | 5 | 2 | 3 |
| Depreciation | 5 | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 20 | 28 |
| Profit before tax | 8 | 14 | 57 | 96 | 167 | 207 | 123 | 166 | 248 | 275 |
| Tax % | 30% | 40% | 31% | 24% | 26% | 27% | 27% | 28% | 24% | 24% |
| 6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | 209 | |
| EPS in Rs | 0.77 | 1.19 | 5.39 | 10.02 | 16.89 | 18.86 | 11.17 | 14.80 | 23.35 | 25.98 |
| Dividend Payout % | -0% | -0% | -0% | 20% | 3% | 3% | 5% | 5% | 4% | 4% |
(S): Standalone figures, shown where consolidated figures are not available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | Sep 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 31 | 40 | 79 | 134 | 254 | 600 | 683 | 799 | 981 | 1,182 | 1,226 |
| 140 | 130 | 90 | 82 | 72 | 27 | 22 | 5 | 5 | 5 | 6 | |
| 55 | 60 | 69 | 105 | 105 | 92 | 98 | 101 | 115 | 154 | 173 | |
| Total Liabilities | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,117 | 1,357 | 1,422 |
| 89 | 91 | 85 | 99 | 100 | 190 | 262 | 310 | 453 | 689 | 735 | |
| CWIP | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 148 | 36 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 63 | 99 | 107 |
| 117 | 120 | 133 | 197 | 267 | 502 | 466 | 399 | 453 | 534 | 573 | |
| Total Assets | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,117 | 1,357 | 1,422 |
(S): Standalone figures, shown where consolidated figures are not available.
Cash Flows
Figures in Rs. Crores
| Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 27 | 28 | 49 | 117 | 76 | 49 | 64 | 113 | 165 | 186 | |
| -27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | -152 | -176 | |
| -2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | -8 | -10 | |
| Net Cash Flow | -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 | 4 | -0 |
| Free Cash Flow | -0 | 23 | 54 | 92 | 29 | -11 | -44 | -32 | 2 | 34 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 158% | 141% | 97% | 146% | 61% | 51% | 73% | 86% | 86% | 84% |
(S): Standalone figures, shown where consolidated figures are not available.
Ratios
| Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99 | 92 | 79 | 60 | 69 | 79 | 67 | 71 | 70 | 97 |
| Inventory Days | 113 | 85 | 77 | 130 | 206 | 172 | 234 | 140 | 205 | 229 |
| Days Payable | 121 | 112 | 110 | 130 | 145 | 91 | 130 | 98 | 129 | 159 |
| Cash Conversion Cycle | 91 | 64 | 45 | 61 | 130 | 160 | 171 | 114 | 146 | 167 |
| Working Capital Days | -69 | -50 | -5 | -40 | 28 | 117 | 168 | 157 | 144 | 147 |
| ROCE % | 14% | 37% | 50% | 60% | 43% | 19% | 22% | 27% | 25% |
(S): Standalone figures, shown where consolidated figures are not available.
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Capacity Utilization % |
|
||||||||
| Export Share of Revenue % of revenue |
|||||||||
| Reactor Capacity KLPD |
|||||||||
| Top 10 Customer Concentration % of revenue |
|||||||||
| Europe Revenue Share % of revenue |
|||||||||
| Anesthetic + Analgesic Therapy Share of Revenue % |
|||||||||
| Asia Revenue Share % of revenue |
|||||||||
| Backward Integration % of revenue |
|||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of November 6, 2026 earnings call for Q2 and H1 FY2026-27 available on website.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Q2 FY27 revenue Rs 206.30 crore; Ambernath facility commissioned and commercial production began.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor Presentation is enclosed for the Results Earnings Call for quarter and half year ended September 30, 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2022
from nse
Concalls
-
Nov 2026Transcript PPT REC
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT REC
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022PPT
-
Feb 2022Transcript
-
Jan 2022Transcript PPT
Niche Products Offerings[1]
The company has a niche product basket of 40+ APIs and is a global leader in Anti-histamines, anti-allergy, Vitamins, Anti-Asthmatics, & Anesthetics.